Reneo Pharmaceuticals Incorporated develops therapies for patients with rare genetic mitochondrial diseases. REN001 is a selective peroxisome proliferator-activated receptor delta agonist in (1) Phase IIb clinical trials in patients with primary mitochondrial myopathies, and (2) Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals was incorporated in 2014 and is headquartered in San Diego, CA.
Name / Ticker | Price | Zen Rating |
---|---|---|
$1.72 | A | |
$44.23 | A | |
$8.00 | A |